Pharmaron Beijing Co., Ltd. (Stock code: 03759) reported an increase in both its H shares listed on the Hong Kong Stock Exchange and its A shares listed on the Shenzhen Stock Exchange for January 2026. The company’s authorized share capital for H shares rose from 301,537,125 to 359,977,887, while its A shares advanced from 1,476,658,400 to 1,477,305,741. By the end of January, the total authorized capital amounted to RMB 1,837,283,628.

In respect of H shares, an additional 58,440,762 new shares were issued on January 22, 2026, pursuant to a placing agreement dated January 14, 2026, bringing the total issued H shares (excluding treasury shares) to 352,714,587. Meanwhile, 7,263,300 H shares remain designated as treasury shares for the 2025 H Share Award and Trust Scheme. On the A-share front, 647,341 new shares were issued on January 28, 2026, under 2021 and 2022 Restricted A Share Incentive Schemes, raising the total issued A shares to 1,477,305,741. The company confirmed that its publicly traded shares continue to meet the applicable public float requirement.